Business Wire

Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments

Share

Incyte (Nasdaq:INCY) today announced efficacy and safety results from a pooled analysis of two randomized, double-blind, vehicle-controlled Phase 3 studies – TRuE-AD1 and TRuE-AD2 – evaluating ruxolitinib cream for the treatment of patients with mild-to-moderate atopic dermatitis (AD). The presentation (FC08.08) will be available on-demand as part of the 29th European Academy of Dermatology and Venereology (EADV) Congress, held virtually from October 29-31, 2020.

Key findings from the individual TRuE-AD1 and TRuE-AD2 studies were previously reported.

The new, pooled data reinforce that treatment with ruxolitinib cream resulted in a rapid, substantial and sustained reduction in itch; and improved the extent and severity of AD as measured by the Eczema Area Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD) assessment tools.

In addition, treatment with ruxolitinib cream resulted in notable improvements in quality of life measures such as the PROMIS (Patient-Reported Outcomes Measurement Information System)1 sleep disturbance (8b)2 score. PROMIS is a set of well-accepted patient-reported outcome measurement tools that are psychometrically supported.1 In the TRuE-AD trials, the PROMIS Short Form-Sleep Disturbance (8b) questionnaire was used to assess patients’ self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep.

Key results from the pooled analysis include:

 

Ruxolitinib cream 0.75% BID

Ruxolitinib cream 1.5% BID

Vehicle

Primary endpoint

IGA-TS, responders

n=483

n=481

n=244

44.7%*

52.6%*

11.5%

Key secondary endpoints

EASI-75, responders

n=483

n=481

n=244

53.8%*

62.0%*

19.7%

Itch NRS (≥4-point improvement) , responders

n=313

n=307

n=158

41.5%*

51.5%*

15.8%

PROMIS Short Form-Sleep Disturbance (8b) (≥6-point improvement) , responders

n=446

n=449

n=226

20.9%**

23.8%**

14.2%

Secondary endpoint

SCORAD, mean change from baseline

n=483

n=481

n=244

-62.9%*

-67.3%*

-30.4%

Additional efficacy analysis

Daily Itch NRS Score, mean change from baseline within 12 hours

n=483

n=481

n=244

-0.4***

-0.5***

-0.1

IGA-TS: Investigator’s Global Assessment (IGA)-Treatment Success defined as an IGA score of 0 (clear) or 1 (almost clear) with ≥2-point improvement from baseline at Week8; BID: twice daily; EASI-75: ≥75% improvement from baseline at Week 8 in the Eczema Area and Severity Index (EASI) score; NRS: Numerical Rating Scale; PROMIS: Patient-Reported Outcomes Measurement Information System; SCORAD: Scoring Atopic Dermatitis.
Patients included in the analysis had an Itch NRS score ≥4 at baseline; Patients included in the analysis had a PROMIS Short Form-Sleep Disturbance (8b) score of ≥6 at baseline.
*P<0.0001 vs. vehicle at Week 8; **P<0.05 vs. vehicle at Week 8; ***P<0.02 vs. vehicle.

The overall safety profile of ruxolitinib cream was consistent with previously reported data, with no new safety signals observed in this pooled analysis.

“Atopic dermatitis is a chronic inflammatory skin condition that may result in decreased quality of life for patients; attributable in part to sleep disturbances resulting from intense and persistent itch,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. “Pooled results from the TRuE-AD studies reinforce the potential of ruxolitinib cream to become an important antipruritic and anti-inflammatory treatment option for patients with atopic dermatitis and we are on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration at the end of this year.”

About Atopic Dermatitis

Atopic dermatitis (AD) is a common chronic and intensely pruritic disease characterized by inflammation of the skin. AD affects more than 30 million individuals in the United States and 80-90% of patients have mild-to-moderate disease. Signs and symptoms of AD include irritated and itchy skin that can cause red lesions that may ooze and crust. Patients with AD are also more susceptible to bacterial, viral and fungal infections.

About TRuE-AD

The TRuE-AD clinical trial program consists of two randomized, double-blind, vehicle-controlled Phase 3 studies, TRuE-AD1 (NCT03745638) and TRuE-AD2 (NCT03745651), evaluating the safety and efficacy of ruxolitinib cream compared to vehicle (non-medicated cream) in patients with atopic dermatitis (AD). Both studies enrolled more than 600 patients (age ≥12 years) diagnosed with AD for at least two years and who were candidates for topical therapy.

Patients with an Investigator’s Global Assessment (IGA) score of 2 to 3, and with AD on 3% to 20% of their Body Surface Area (excluding scalp) were randomized 2:2:1 into one of three arms for eight weeks: ruxolitinib cream 0.75% applied twice daily (BID); ruxolitinib cream 1.5% applied BID; and vehicle. Participants who successfully completed an assessment at Week 8 were offered participation in the 44-week long-term safety treatment extension period with ruxolitinib cream 0.75% or 1.5% applied BID.

The primary endpoint of the TRuE-AD studies was the proportion of participants achieving an Investigator’s Global Assessment Treatment Success (IGA-TS), defined as an IGA score of 0 (clear) or 1 (almost clear) with at least a 2-point improvement from baseline at Week 8. Key secondary endpoints include: the proportion of patients achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index (EASI-75) score, the proportion of participants with at least a 4-point improvement in the itch Numerical Rating Scale, and the proportion of participants with at least a 6-point improvement in the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form – Sleep Disturbance (8b) 24-hour recall score. Additional secondary endpoints include mean percentage change from baseline in Scoring Atopic Dermatitis (SCORAD) score. The studies have also been tracking the frequency, duration and severity of adverse events associated with the use of ruxolitinib cream.

For more information about the TRuE-AD studies, please visit http://clinicaltrials.gov/ct2/show/NCT03745638 and http://clinicaltrials.gov/ct2/show/NCT03745651 .

About Ruxolitinib Cream

Ruxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of patients with mild-to-moderate atopic dermatitis (TRuE-AD) and for the treatment of adolescents and adults with vitiligo (TRuE-V). Incyte has worldwide rights for the development and commercialization of ruxolitinib cream.

About Incyte Dermatology

Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company’s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function.

Currently, Incyte is exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa. To learn more, visit the Dermatology section of Incyte.com.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements about the potential of ruxolitinib cream to provide a meaningful treatment for patients with atopic dermatitis, the TRuE-AD clinical program, the Company’s Dermatology program, the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis, and expected timing of the filing of the NDA for ruxolitinib cream for the treatment of atopic dermatitis, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the efficacy or safety of the Company’s products; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.

PROMIS® is a registered trademark of the U.S. Department of Health and Human Services.

References:

  1. PROMIS. HealthMeasures. Available at: https://www.healthmeasures.net/explore-measurement-systems/promis. Accessed on October 28, 2020.
  2. Buysse DJ, et. al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep 2010; 33:781-792.

Contact information

Media

Catalina Loveman, +1 302 498 6171
cloveman@incyte.com

Nupur Patel, PharmD, +1 302 498 5822
npatel@incyte.com

Investors

Michael Booth, DPhil, +1 302 498 5914
mbooth@incyte.com

Christine Chiou, +1 302 274 4773
cchiou@incyte.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhancing the HD-PLC™ Security Functions25.11.2020 17:00:00 EETPress release

HD-PLC Alliance *1 has started standardization work that will allow the use of enhanced network security functions, with the aim of using High-Definition Power Line Communication technology in the fields of smart grids and distributed power management. HD-PLC™*2 (hereinafter referred to as HD-PLC) technology has already been standardized as IEEE 1901 (Broadband over Power Line Networks for MAC and PHY) by the IEEE Standards Association*3 . This technology is particularly attracting attention in Europe as a communication infrastructure that can be used for distributed power management of energy. Therefore, the current security functions will be enhanced and expanded, including making the technology compatible with strong authentication functions required for use in large-scale networks. Current HD-PLC technology offers extremely high security at the device level, including continuous encrypted communication and authentication between compatible devices. However, for PLC equipment to be

ViacomCBS to Sell Simon & Schuster to Penguin Random House for $2.175 Billion25.11.2020 17:00:00 EETPress release

ViacomCBS Inc. (NASDAQ: VIAC, VIACA) today announced it has entered into a definitive agreement to sell the publishing business Simon & Schuster (“Simon & Schuster”) to Penguin Random House LLC (“Penguin Random House”), a wholly owned subsidiary of Bertelsmann SE & Co. KGaA, for $2.175 billion in cash. This divesture follows a strategic review of non-core assets ViacomCBS undertook early in 2020. Proceeds from the transaction will be used to invest in ViacomCBS’s strategic growth priorities, including in streaming, as well as to fund the dividend and pay down debt. This transaction is the outcome of a highly competitive auction that attracted interest from buyers around the world, reflecting Simon & Schuster’s position as one of the world’s best known publishing brands. Simon & Schuster has more than 30 publishing units across adult, children, audio and international. Its portfolio of best-selling authors includes Stephen King, Doris Kearns Goodwin and Jason Reynolds, and it owns a ric

Northern Data AG Commissions First Data Center in the Netherlands25.11.2020 16:11:00 EETPress release

Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), a leading provider of High-Performance Computing (HPC) solutions, is commissioning its latest HPC data center near Maastricht. This new facility will entail one of the largest GPU clusters worldwide and will be the Company's first data center location in the European Union. The Company will begin installing the first hardware for its GPU-based Distributed Computing Cluster from the beginning of December. The GPU cluster is one of Northern Data AG's most significant expansion steps and is expected to be scaled up by the end of Q1/2021 to achieve computing power of 404 Petaflops (FP64). With this level of power, it will be one of the largest GPU clusters of its kind worldwide. The world's most powerful supercomputer, Japan's Fugaku, has a computing capacity of 415 Petaflops. As CEO Aroosh Thillainathan commented: "With the smooth and rapid expansion of our GPU cluster, now including our first European location, we are moving to meet the

LexFinance Announced a Favorable Partial Award in a US$ 28 Billion Arbitration Against Brazil and for the Benefit of Petrobras25.11.2020 16:00:00 EETPress release

LexFinance announced a favorable partial award in a US$ 28 billion arbitration against Brazil and for the benefit of Petrobras. The claim has been filed by a minority shareholder of Petrobras against the Brazilian Government for the economic losses suffered by Petrobras due to corruption practices disclosed in the Car Wash investigation and caused by the abuse of power of the Brazilian Government as controlling shareholder of Petrobras. The partial award recognized the arbitrability of the dispute, that the Brazilian Government is subject to the arbitration clause and the standing of the claimant funded by LexFinance to act on behalf and for the benefit of Petrobras. If the damages are confirmed in the last phase of the arbitration expected to conclude during 2021, the Brazilian Government will have to compensate Petrobras for losses currently estimated at US$ 28 billion. In addition, according to article 246 of the Brazilian Corporate Law, it will have to pay to the claimant funded by

Last and Final Victory for Sisvel Before the German Federal Supreme Court (BGH) In the Sisvel vs Haier Cases25.11.2020 15:29:00 EETPress release

Yesterday the German Federal Supreme Court heard the oral arguments in another patent infringement case between Sisvel and Haier regarding Sisvel’s request for injunctive relief for infringement of cellular standard essential patents (SEPs) it owns. The decision rendered yesterday marks the final decision regarding Haier’s infringement of Sisvel’s European patent EP 1 264 504 (“EP 504”), and the related FRAND defense after a 6 year long legal dispute. Prior to this verdict, the BGH (1) confirmed the German part of Sisvel’s EP 504 valid on April 28, 2020, (2) confirmed the German part of Sisvel’s EP 0 852 885 B1 (“EP 885”) valid on March 10, 2020, and (3) reversed the Düsseldorf Court of Appeal’s 2017 decision that wrongly considered Haier a willing licensee on May 5, 2020. In the motivation of the BGH May 2020 decision, it provided helpful guidance on certain aspects of the FRAND negotiation process (see https://www.sisvel.com/news-events/news/clarifications-on-licensing-of-standard-es

Advanced Technology Research Council Announces ‘ASPIRE’ – to Drive the Creation of Future Transformative Technologies25.11.2020 14:22:00 EETPress release

The newly established Advanced Technology Research Council (ATRC) has today announced its plans to drive the creation of future transformative technologies with the launch of its dedicated technology programme management pillar, ASPIRE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005562/en/ His Excellency Faisal Al Bannai, Secretary-General of Advanced Technology Research Council (Photo: AETOSWire) ASPIRE works in consultation with cross-sector industry stakeholders to frame problem statements that can be solved through research and development. By defining the problem, setting milestones, and monitoring the progress of the projects, ASPIRE facilitates a clear path from ‘lab to market.’ ASPIRE will make impactful decisions related to the selection of research partners and the allocation of funding. It will ensure that its R&D priorities align with Abu Dhabi and the UAE's broader development goals. ASPIRE will also l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom